Ibrutinib as second-line therapy for chronic lymphocytic leukemia supported by study

In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia, ibrutinib significantly outperformed ofatumumab as a second-line therapy, according to a multicenter interim study. Ibrutinib is the first drug designed to target Bruton's tyrosine kinase, a protein essential for CLL-cell survival and proliferation.